Jenscare Scientific Co. Ltd. has announced promising results from its recent studies on two innovative medical devices. The 30-day follow-up results from the global multicenter clinical trial of the LuX-Valve Plus transcatheter tricuspid valve replacement, known as the TRINITY study, as well as the one-year follow-up data from the JensClip transcatheter mitral valve repair system, were unveiled at EuroPCR 2025 in Paris. The findings indicate that 96.3% of patients experienced no regurgitation above moderate levels. Additionally, improvements were noted in various indicators such as the New York Heart Association cardiac function, Kansas City Cardiomyopathy Questionnaire scores, and six-minute walking distance. Jenscare Scientific aims to continue advancing the application and commercialization of these products globally, although it cautions that there is no guarantee of ultimate success in development and marketability.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。